NovaBay stock: buy or sell?
September 20th, 2019
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States.
Should I buy NovaBay stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with NovaBay Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NovaBay stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we found 1 rating published for NBY stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-18||LADENBURG THALM/SH SH||n/a||Buy|
NovaBay stock analysis
After boosting a dazzling 12.66% on Sep 19th, NovaBay Pharmaceuticals closed yesterday at $0.69 and plunged a frightening -12.66%.
After boosting a dazzling 12.66% on September 19th, NovaBay Pharmaceuticals closed yesterday at $0.69 and plunged a frightening -12.66%. Since last August when NBY stock price broke down the SMA200d line, it slid $-0.61 per share (-46.92%).
NovaBay climbed a dazzling 32.69% this week. Late August NBY plummed a scary -16.67% in just one week.
Price pattern shows an uptrend with two rising tops and bottoms, and now trading upwards to the $4.04 resistance.
NovaBay stock price history
NovaBay stock went public on October 26th, 2007 with a price of $105.001. Since then, NBY stock sliced a -99.30%, with a yearly average of -9.00%.
1: Adjusted price after possible price splits or reverse-splits.
NovaBay stock historical price chart
NBY stock reached 52-week highs on June at $4.04, and all-time highs 2007-10-26 with a price of 106.25.
NovaBay stock price target is $1.10Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NBY stock price predictions in the hope that they will be met as they may be wrong and not met. Currently, only 1 price prediction for NovaBay stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-18||LADENBURG THALM/SH SH||Initiates||n/a||$1.10||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, NovaBay missed the forecasts of the analysts and posted a bloodcurdling EPS of $-0.09 per share when experts were expecting $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a chilling loss of -31.39% to $12.51 M dollars. In the same way, its income margin (compared to sales) collapsed to -52.33%, that is $-6.55 million.
|2013||$3.48 M||-||$-16.04 M-460.9%||-|
|2014||$1.05 M||-69.71%||$-15.19 M-1441.6%||-5.27%|
|2015||$4.38 M||315.65%||$-18.97 M-433.1%||24.87%|
|2016||$12 M||171.56%||$-13.15 M-110.5%||-30.69%|
|2017||$18 M||53.23%||$-7.40 M-40.6%||-43.71%|
|2018||$13 M||-31.39%||$-6.55 M-52.3%||-11.59%|
Quarterly financial resultsNovaBay reported $3.63 M in sales for 2018-Q4, a 15.37% up compared to previous quarter. Reported quarter income marked $-1.27 M with a profit margin of -34.98%. Profit margin rocketed a 13.97% compared to previous quarter when profit margin was -48.95%. When comparing sales to same quarter last year, NovaBay Pharmaceuticals sales marked a dreadful drop down and plummed a -42.61%. Looking back to recent quarterly results, NovaBay posted 2 positive quarters in a row.
|2017-Q1||$4 M||-||$-4.01 M-108.4%||-|
|2017-Q2||$4 M||11.35%||$-1.74 M-42.2%||-56.61%|
|2017-Q3||$4 M||-0.70%||$-2.45 M-59.8%||40.63%|
|2017-Q4||$6 M||54.39%||$0.79 M12.6%||-132.41%|
|2018-Q1||$3 M||-53.34%||$-2.15 M-73.0%||-371.12%|
|2018-Q2||$3 M||-5.19%||$-1.59 M-56.9%||-26.09%|
|2018-Q3||$3 M||12.46%||$-1.54 M-48.9%||-3.21%|
|2018-Q4||$4 M||15.37%||$-1.27 M-35.0%||-17.56%|
NovaBay ownershipWhen you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.
NovaBay Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 25.87% of all shares.
In case of NovaBay Pharmaceuticals stock, 4.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NBY stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$17.4 M||$347.6 B||$13.8 M||$449.8 M||$9.0 M|
|Total shares||25.2 M||2,640.0 M||76.9 M||81.1 M||1.3 M|
|Float shares||8.7 M||2,630.0 M||54.6 M||49.8 M||1.3 M|
|- Institutional holdings (%)||4.1%||69.2%||5.0%||30.2%||14.5%|
|- Insider holdings (%)||25.9%||0.1%||28.1%||33.0%||2.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$0.64 - $0.78|
|Average true range||$0.11|
|50d mov avg||$0.86|
|100d mov avg||$0.99|
|200d mov avg||$1.13|
NovaBay performanceTo better understand NovaBay Pharmaceuticals performance you must becnhmark its gains with other related stocks in same sector or industry. For NovaBay, the benchmark is made against , NanoViricides, SIGA Technologies, Sonoma Pharmaceuticals and Tetraphase Pharmaceuticals.